Capsugel – Now a Lonza Company

As the pharmaceutical developers transition from blockbuster APIs to niche busters, they are facing new challenges with formulating poorly absorbable APIs. This webcast will provide a brief overview of the market dynamics and discuss in detail possible oral dosage form solutions to help overcome challenges with bioavailability and absorption of complex drug formulations.

Provide a better understanding of lipid-based formulations and how they help improve bioavailability.

Discuss amorphous solid dispersions and how it can improve absorption.

Review possible oral dosage form solutions and tips on how to choose the right capsule to meet development requirements.

: Tuesday, May 18, 2021 at 11am EDT |8am PDT| 4pm BST| 5pm CEST

On demand available after final airing until May 18, 2022

Webcasts

Two Airings! * NA, EMEA, LATAM: Tuesday, May 18, 2021 at 11am EDT |8am PDT| 4pm BST| 5pm CEST and APAC: Tuesday, May 25, 2021 at 4pm JST| 3pm CST| 5pm AEST| 12:30pm IST* Learn more about possible solutions to help overcome the challenges of formulating poorly absorbable APIs with different oral dosage forms. *On Demand Until May 25, 2022* 

Enabling Formulations of Poorly Absorbable Drugs with Capsule Solutions 

	Dry-powder inhalation is a major drug delivery technology for the treatment of respiratory diseases and, increasingly, for systemic drug delivery. Providing a uniform dose in a portable, easy-to-use system, capsule-based dry-powder inhalers (DPIs) are a simple and cost-effective way to deliver medication by the pulmonary route.

	Polymer science and engineering have opened a new era of functional development, which offers the potential for selecting the optimal capsule for different active pharmaceutical ingredients (APIs) and various inhalation devices. These capabilities also can be associated with a wider range of services.

	Within the dry-powder inhalation application fields, Lonza offers a portfolio of high-quality capsule solutions based on different polymers, tailored to enable consistent and optimal release performance. Building on a history of innovation in polymer science and capsule engineering, the Capsugel® brand, now part of Lonza, offers a suite of HPMC and alternate polymer capsules for the pharmaceutical world.

 Dry-Powder Inhalation Capsule Portfolio, visit:

www.capsugel.com/biopharmaceutical-products/dpi-capsules

Articles

Dry-powder inhalation (DPI) technology offers a favorable drug development opportunity for respiratory or systemic drug delivery. Delivering a uniform dose in a portable, easy-to-use system, capsule-based DPI device is a simple and cost-effective way to deliver inhalable medication.